Antibiotic Use in the 12 Months Prior to Ileal Pouch-Anal Anastomosis Increases the Risk for Pouchitis

Edward L Barnes1, Anastasia Karachalia Sandri2, Hans H Herfarth1

  • 1Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Multidisciplinary Center for Inflammatory Bowel Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

Insights

Antibiotic exposure before ileal pouch-anal anastomosis (IPAA) surgery for ulcerative colitis (UC) increases the risk of developing pouchitis. This finding highlights a potential modifiable risk factor for this common post-surgical complication.

Area of Science:

  • Gastroenterology
  • Surgical Complications
  • Inflammatory Bowel Disease Research

Background:

  • Pouchitis is the most frequent complication following ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC).
  • Clinical and environmental risk factors contributing to pouchitis development are not well understood.
  • Identifying these factors is crucial for managing post-IPAA complications.

Purpose of the Study:

  • To investigate the association between specific clinical factors and the incidence of pouchitis.
  • To determine if antibiotic exposure, NSAID use, or appendectomy influences pouchitis risk post-IPAA.
  • To provide evidence for potential preventative strategies.

Main Methods:

  • A population-based cohort study was conducted in Denmark, including adult UC patients who underwent IPAA between 1996 and 2020.
  • Cox proportional hazard modeling was employed to analyze the impact of pre-operative antibiotic, NSAID exposure, and appendectomy on acute pouchitis diagnosis within two years.
  • Adjustments were made for anti-tumor necrosis factor alpha use and patient sex.

Main Results:

  • Out of 1616 patients, 46% developed pouchitis within two years of IPAA.
  • Antibiotic exposure in the 12 months preceding IPAA significantly increased pouchitis risk (aHR, 1.41).
  • The risk escalated with the number of antibiotic courses (1-2 courses: aHR, 1.30; 3+ courses: aHR, 1.77), while NSAID use and appendectomy showed no significant association.

Conclusions:

  • Pre-operative antibiotic exposure within a year of IPAA is a significant risk factor for acute pouchitis in UC patients.
  • This finding suggests a potential target for intervention to reduce pouchitis incidence.
  • Further research into microbial changes in at-risk patients is recommended for early intervention strategies.
Abstract

Related Concept Videos

Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
145
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
233
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
179
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
127